Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good day, and thank you for standing by. Welcome to the Arcutis ...

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on ...

As the future of rare disease research at Cincinnati Children's is threatened, parents of 13-year-old Charlie Evans plead for its reinstatement.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Sanofi’s latest earnings call reflects a positive outlook for the company, marked by strong sales growth, strategic acquisitions, and a commitment to sustainability. Despite some challenges, such as ...

KanawatTH Most major stock indexes across the globe ended the week lower over tariff jitters, while the focus also remained ...

Viking Therapeutics ' ( VKTX 0.28%) shares could rise over the next year by as much as 165% at the midpoint according to some ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...